AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Investors / Strategy

Strategy

March 15, 2017 By antoxa

Focus on national stockpiles

The Company’s initial focus is to develop and market biologic drugs for stockpiling by government agencies. This strategy can expand into co-developing innovative drugs with government partners. The company has also successfully implemented a program conducting contract drug development work and manufacturing for other organizations. Clients have included the Government of Canada and an Asian pharmaceutical company.

In order to seize this growing opportunity, AntoXa is seeking a Series A round of $5 million to advance product opportunities and later will offer a Series B round of $15 million to establish a Canadian manufacturing facility.

By using the vivoXPRESS® system and its own manufacturing facility, AntoXa will be able to produce affordable medical countermeasures at significantly lower costs compared to competitive products made in traditional mammalian cell culture systems.

AntoXa has the solution to a potentially deadly problem that, although impossible to predict, is almost certain to happen.

Filed Under: Investors

Latest News

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

August 17, 2021

DRDC-funded project aims to develop recombinant human ...
Read more >

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2022 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates